מן הרשת 06.03.202513:00 Towards a biological view of multiple sclerosis from early subtle to clinical progression an expert opinion Journal of Neurology
מן הרשת 06.03.202512:59 Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs) a systematic review and meta-analysis Journal of Neurology
מן הרשת 06.03.202512:44 Fatigue in multiple sclerosis: can we measure it and can we treat it? This paper describes the challenges clinicians and researchers face when assessing and treating MS patients, as well as our understanding of neural mechanisms involved in fatigue Journal of Neurology
מן הרשת 06.03.202512:40 Treatment discontinuation in older people with multiple sclerosis The aim of this review was to examine the evidence for disease-modifying therapies (DMTs) discontinuation in older people with multiple sclerosis (MS) Current Opinion in Neurology
מן הרשת 06.03.202512:39 Cognitive Impairment in Multiple Sclerosis Past, Present, and Future Neuroimaging Clinics of North America
מן הרשת 06.03.202512:37 Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance CNS Drugs
מן הרשת 06.03.202512:36 Management of multiple sclerosis in older adults review of current evidence and future perspectives Journal of Neurology
מן הרשת 11.09.202411:58 Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions in MS Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS Neurology
מן הרשת 11.09.202411:57 Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients Objective: To investigate the association of sNfL and sGFAP with cognitive decline in MS patients at high risk for progressive pathology Mult Scler
מן הרשת 11.09.202411:56 Unveil the Pathobiological Foundations of Multiple Sclerosis Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis Neurology
מן הרשת 11.09.202411:54 Smouldering-Associated Worsening in Multiple Sclerosis An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions Ann Neurol
מן הרשת 07.01.202411:30 Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review Across its clinical development program, ocrelizumab demonstrated efficacy in improving clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed disability progression Ann Clin Transl Neurol
מן הרשת 07.01.202411:28 Expert opinion on the long-term use of cladribine tablets for multiple sclerosis Systematic literature review of real-world evidence Mult Scler
מן הרשת 07.01.202411:27 Emerging therapies to target CNS pathophysiology in multiple sclerosis The rapidly evolving therapeutic landscape of multiple sclerosis (MS) has contributed to paradigm shifts in our understanding of the biological mechanisms that contribute to CNS injury and in treatment philosophies Nature Reviews Neurology
מן הרשת 07.01.202411:26 Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors A Review JAMA Neurol